跳至主要内容
临床试验/CTRI/2024/03/063895
CTRI/2024/03/063895尚未招募Unknown

The Efficacy Of Imeglimin Compared To Metformin In Dual Therapy With Dpp-4 Inhibitor On Glycemic Control And Weight Management: A Randomized Controlled Trial - NI

SRM College of Pharmacy, SRM Institute of Science and Technology0 个研究点目标入组 110 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Individuals presenting with T2DM fulfilling the following criteria: QUIKI Index <0.36, KIER Scoring System >60, Fasting Blood glucose 110- 250 mg/dl, HbA1c 6.5-9.0 % , Score of 3-4 on the DSMQ Scale

排除标准

  • Glycated Hemoglobin Above 10.0%
  • Planned To Start Treatment with Insulin During the Intervention Period.
  • Patients with severe Heart (Congenital Heart Failure, Valve diseases, Unstable Angina), Liver (Decompensated Liver Disease, Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease), Or Kidney Disease (chronic kidney disease stage II –IV) or Incurable Cancer.
  • Patients with Type 1 Diabetes Mellitus.
  • Prior history of ketoacidosis.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Women who are on gestation, lactating, nursing and who plan to become pregnant will be excluded.

研究者

发起方
SRM College of Pharmacy, SRM Institute of Science and Technology

相似试验